Alok Pachori
Medical Director, Global Development AstraZeneca
Seminars
Wednesday 15th April 2026
Targeting Liver Metabolic & Inflammatory Pathways for Treatment of MASH
10:00 am
- MASH is a progressive inflammatory form of MASLD and is a leading cause of chronic liver disease worldwide
- Therapeutic strategies targeting metabolic dysfunction, inflammation and fibrosis are urgently needed
- Combination therapies and precision medicine approaches targeting these pathways will lead to histological improvement and patient reported outcomes
- Therapies targeting novel inflammatory processes may change the course of treatment of MASH
